

# **Global Artemisinin Market Size study, by Malaria Type (Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Ovale, Plasmodium Malariae, Plasmodium Knowlesi), Product (Injections, Tablets), Type (Combination, Monotherapy) and Regional Forecasts 2022-2032**

<https://marketpublishers.com/r/G99CFCBAEB38EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: G99CFCBAEB38EN

## **Abstracts**

Global Artemisinin Market is valued approximately at USD 0.67 billion in 2023 and is anticipated to grow with a steady CAGR of more than 4.2% over the forecast period 2024–2032. Artemisinin, a naturally derived antimalarial compound sourced from the *Artemisia annua* plant, has emerged as the cornerstone of modern malaria therapy. Its potent efficacy, particularly against drug-resistant strains of *Plasmodium falciparum*, has led to widespread adoption across both monotherapy and combination treatments. As malaria continues to pose a major health burden, especially across tropical and subtropical regions, the strategic role of artemisinin-based therapies remains paramount in global health initiatives aiming to curb and eliminate the disease.

The market's momentum is being accelerated by growing malaria prevalence in sub-Saharan Africa and parts of Southeast Asia, prompting increased government procurement of artemisinin-based combination therapies (ACTs). With international agencies like WHO and Global Fund supporting subsidized treatment access and stockpile reserves, the commercial production of artemisinin and its derivatives has scaled substantially. Meanwhile, pharmaceutical manufacturers are developing novel formulations—such as artemisinin-piperaquine fixed-dose combinations and long-acting injectables—to enhance compliance and therapeutic impact. Further, growing awareness of plant-based APIs and integrated vector control programs are expected to complement the demand trajectory through 2032.

Nevertheless, challenges persist that could restrain the market from achieving its full potential. The volatility in artemisinin raw material pricing—due to weather-dependent cultivation—poses a supply chain risk. Additionally, emerging resistance to ACTs in parts of Southeast Asia and Oceania threatens to undermine treatment efficacy, urging a need for next-gen derivatives and resistance-monitoring systems. Furthermore, limited production infrastructure in low-income countries and quality compliance issues remain areas that necessitate regulatory and logistical interventions. However, biotechnological breakthroughs in semi-synthetic artemisinin synthesis and expanding research into artemisinin-based cancer and anti-inflammatory therapies offer promising avenues for diversification and market expansion.

Technological advancements are redefining artemisinin manufacturing through synthetic biology approaches and fermentation-based methods, which aim to stabilize supply chains and reduce ecological dependency. Simultaneously, the growing trend of public-private partnerships, especially between global health bodies and pharma producers, is fostering innovation and ensuring equitable access. The rise of e-pharmacies and digitized distribution networks has further strengthened last-mile delivery of malaria treatments in remote areas, paving the way for enhanced market penetration and real-time stock monitoring.

Regionally, the Asia Pacific market dominates the artemisinin industry, led by high malaria-endemic zones and a strong production base in China and Vietnam. Africa follows closely, driven by large-scale donor-funded healthcare campaigns and a rising commitment from national health ministries. Latin America is showing a steady uptake, supported by WHO's malaria elimination roadmap in the region. Meanwhile, North America and Europe, though low in malaria burden, are contributing to the market via research grants, vaccine integration trials, and export of pharmaceutical-grade artemisinin derivatives.

**Major market player included in this report are:**

Guilin Pharmaceutical Co., Ltd.

Sanofi S.A.

Novartis AG

Cipla Limited

IPCA Laboratories Ltd.

Zhenhua Pharma Co., Ltd.

Artecef B.V.

KPC Pharmaceuticals, Inc.

Calyx Chemicals and Pharmaceuticals Ltd.

Shanghai Natural Bio-engineering Co., Ltd.

Zhifei Biological Products Co., Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Zhejiang Holley Pharmaceutical Co., Ltd.

Guangdong New South Group Co., Ltd.

Ajanta Pharma Ltd.

**The detailed segments and sub-segment of the market are explained below:**

By Malaria Type

Plasmodium Falciparum

Plasmodium Vivax

Plasmodium Ovale

Plasmodium Malariae

Plasmodium Knowlesi

## By Product

Injectables

Tablets

## By Type

Combination

Monotherapy

## By Region:

### North America

U.S.

Canada

### Europe

UK

Germany

France

Spain

Italy

Rest of Europe

### Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

**Years considered for the study are as follows:**

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

## Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with country-level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

## Companies Mentioned

Guilin Pharmaceutical Co., Ltd.

Sanofi S.A.

Novartis AG

Cipla Limited

IPCA Laboratories Ltd.

Zhenhua Pharma Co., Ltd.

Artecef B.V.

KPC Pharmaceuticals, Inc.

Calyx Chemicals and Pharmaceuticals Ltd.

Shanghai Natural Bio-engineering Co., Ltd.

Zhifei Biological Products Co., Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Zhejiang Holley Pharmaceutical Co., Ltd.

Guangdong New South Group Co., Ltd.

Ajanta Pharma Ltd.

## Contents

### **CHAPTER 1. GLOBAL ARTEMISININ MARKET EXECUTIVE SUMMARY**

- 1.1. Global Artemisinin Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
  - 1.3.1. By Malaria Type
  - 1.3.2. By Product
  - 1.3.3. By Type
- 1.4. Key Trends
- 1.5. COVID-19 Impact
- 1.6. Analyst Recommendation & Conclusion

### **CHAPTER 2. GLOBAL ARTEMISININ MARKET DEFINITION AND RESEARCH ASSUMPTIONS**

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
  - 2.3.1. Inclusion & Exclusion
  - 2.3.2. Limitations
  - 2.3.3. Supply Side Analysis
    - 2.3.3.1. Raw Material Availability
    - 2.3.3.2. Cultivation Infrastructure
    - 2.3.3.3. Regulatory Environment
    - 2.3.3.4. Manufacturing Capacity
    - 2.3.3.5. Cost Viability
  - 2.3.4. Demand Side Analysis
    - 2.3.4.1. Public Health Programs
    - 2.3.4.2. Technological Advancements
    - 2.3.4.3. Environmental Factors
    - 2.3.4.4. Healthcare Access & Compliance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

### **CHAPTER 3. GLOBAL ARTEMISININ MARKET DYNAMICS**



### 3.1. Market Drivers

- 3.1.1. Rising Malaria Incidence in Endemic Regions
- 3.1.2. Global Health Initiatives for ACT Procurement
- 3.1.3. Innovations in Fixed-Dose Combinations and Long-Acting Injectables

### 3.2. Market Challenges

- 3.2.1. Raw Material Price Volatility Due to Cultivation Risks
- 3.2.2. Emerging Artemisinin Resistance in Southeast Asia

### 3.3. Market Opportunities

- 3.3.1. Semi-Synthetic and Fermentation-Based Artemisinin Production
- 3.3.2. Expansion of E-Pharmacy and Digital Distribution Models
- 3.3.3. Research into Non-Malaria Indications (e.g., Oncology)

## **CHAPTER 4. GLOBAL ARTEMISININ MARKET INDUSTRY ANALYSIS**

### 4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Future Outlook on Five Forces
- 4.1.7. Impact Analysis

### 4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

### 4.3. Top Investment Opportunities

### 4.4. Winning Strategies

### 4.5. Disruptive Trends

### 4.6. Expert Opinions

### 4.7. Analyst Recommendation & Conclusion

## **CHAPTER 5. GLOBAL ARTEMISININ MARKET SIZE & FORECASTS BY MALARIA TYPE, 2022–2032**

### 5.1. Segment Dashboard

- 5.2. Plasmodium Falciparum
- 5.3. Plasmodium Vivax
- 5.4. Plasmodium Ovale
- 5.5. Plasmodium Malariae
- 5.6. Plasmodium Knowlesi

## **CHAPTER 6. GLOBAL ARTEMISININ MARKET SIZE & FORECASTS BY PRODUCT, 2022–2032**

- 6.1. Segment Dashboard
- 6.2. Injections
- 6.3. Tablets

## **CHAPTER 7. GLOBAL ARTEMISININ MARKET SIZE & FORECASTS BY TYPE, 2022–2032**

- 7.1. Segment Dashboard
- 7.2. Combination Therapy
- 7.3. Monotherapy

## **CHAPTER 8. GLOBAL ARTEMISININ MARKET SIZE & FORECASTS BY REGION, 2022–2032**

- 8.1. North America Artemisinin Market
  - 8.1.1. U.S. Artemisinin Market
  - 8.1.2. Canada Artemisinin Market
- 8.2. Europe Artemisinin Market
  - 8.2.1. UK Artemisinin Market
  - 8.2.2. Germany Artemisinin Market
  - 8.2.3. France Artemisinin Market
  - 8.2.4. Spain Artemisinin Market
  - 8.2.5. Italy Artemisinin Market
  - 8.2.6. Rest of Europe
- 8.3. Asia Pacific Artemisinin Market
  - 8.3.1. China Artemisinin Market
  - 8.3.2. India Artemisinin Market
  - 8.3.3. Japan Artemisinin Market
  - 8.3.4. Australia Artemisinin Market
  - 8.3.5. South Korea Artemisinin Market

- 8.3.6. Rest of Asia Pacific
- 8.4. Latin America Artemisinin Market
  - 8.4.1. Brazil Artemisinin Market
  - 8.4.2. Mexico Artemisinin Market
  - 8.4.3. Rest of Latin America
- 8.5. Middle East & Africa Artemisinin Market
  - 8.5.1. Saudi Arabia Artemisinin Market
  - 8.5.2. South Africa Artemisinin Market
  - 8.5.3. Rest of Middle East & Africa

## **CHAPTER 9. COMPETITIVE INTELLIGENCE**

- 9.1. Key Company SWOT Analysis
  - 9.1.1. Guilin Pharmaceutical Co., Ltd.
  - 9.1.2. Sanofi S.A.
  - 9.1.3. Novartis AG
- 9.2. Top Market Strategies
- 9.3. Company Profiles
  - 9.3.1. Guilin Pharmaceutical Co., Ltd.
    - 9.3.1.1. Key Information
    - 9.3.1.2. Overview
    - 9.3.1.3. Financial (Subject to Data Availability)
    - 9.3.1.4. Product Summary
    - 9.3.1.5. Market Strategies
  - 9.3.2. Cipla Limited
  - 9.3.3. IPCA Laboratories Ltd.
  - 9.3.4. Zhenhua Pharma Co., Ltd.
  - 9.3.5. Artecef B.V.
  - 9.3.6. KPC Pharmaceuticals, Inc.
  - 9.3.7. Calyx Chemicals and Pharmaceuticals Ltd.
  - 9.3.8. Shanghai Natural Bio-engineering Co., Ltd.
  - 9.3.9. Zhifei Biological Products Co., Ltd.
  - 9.3.10. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  - 9.3.11. Zhejiang Holley Pharmaceutical Co., Ltd.
  - 9.3.12. Guangdong New South Group Co., Ltd.
  - 9.3.13. Ajanta Pharma Ltd.

## **CHAPTER 10. RESEARCH PROCESS**

## 10.1. Research Process Overview

10.1.1. Data Mining

10.1.2. Analysis

10.1.3. Market Estimation

10.1.4. Validation

10.1.5. Publishing

## 10.2. Research Attributes

## List Of Tables

### LIST OF TABLES

TABLE 1. Global Artemisinin market, report scope

TABLE 2. Global Artemisinin market estimates & forecasts by Region 2022–2032 (USD Million)

TABLE 3. Global Artemisinin market estimates & forecasts by Malaria Type 2022–2032 (USD Million)

TABLE 4. Global Artemisinin market estimates & forecasts by Product 2022–2032 (USD Million)

TABLE 5. Global Artemisinin market estimates & forecasts by Type 2022–2032 (USD Million)

TABLE 6. Global Artemisinin market by segment, estimates & forecasts, 2022–2032 (USD Million)

... (complete list will exceed 20 tables)

## List Of Figures

### LIST OF FIGURES

- FIG 1. Global Artemisinin market, research methodology
- FIG 2. Global Artemisinin market, estimation techniques
- FIG 3. Global Artemisinin market size trends & forecast methods
- FIG 4. Global Artemisinin market, key trends 2023
- FIG 5. Global Artemisinin market, growth outlook 2022–2032
- FIG 6. Global Artemisinin market, Porter's Five Forces
- FIG 7. Global Artemisinin market, PESTEL analysis
- FIG 8. Global Artemisinin market, value chain analysis
- FIG 9. Artemisinin market by Malaria Type, 2022 vs. 2032 (USD Million)
- FIG 10. Artemisinin market by Product, 2022 vs. 2032 (USD Million)
- FIG 11. Artemisinin market by Type, 2022 vs. 2032 (USD Million)
- FIG 12. Artemisinin regional snapshot 2022 vs. 2032
- ... (complete list will exceed 20 figures)

## I would like to order

Product name: Global Artemisinin Market Size study, by Malaria Type (Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Ovale, Plasmodium Malariae, Plasmodium Knowlesi), Product (Injections, Tablets), Type (Combination, Monotherapy) and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G99CFCBAEB38EN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G99CFCBAEB38EN.html>